BOZEN, Italy, January 5 /PRNewswire/ -- Health Robotics today announced that the European Union (EU) Commission and eTen have made available the first results of the SafeChemo Project it sponsored at three of its pharmacies. The EU's SafeChemo objectives were to scientifically and independently establish if CytoCare(TM) (the world's first and only automated robotic system for the safe preparation of hazardous patient-specific IV medications) could improve patient safety for Oncology patients, eradicate injuries and contamination risks associated with handling Oncology IVs, and reduce costs as compared to manual compounding of cancer drugs.
"I'm delighted with the outcome of the SafeChemo project because it independently and scientifically authenticates CytoCare(TM) features and benefits, providing additional evidence of our success to prospective CytoCare(TM) customers, and comparing and contrasting these results with our competitors' claims that pharmacies should take great risks by solely relying on vendor's advertised specs and factory self-tests without the need for independent validations", said Werner Rainer, CEO of Health Robotics.
Asked about her overall impression, Ann Jacklin, Chief of Service,
Pharmacy and Therapy Services at Imperial College Healthcare NHS Trust in
London, stated: "Studies on CytoCare(TM) are now largely completed, including
tests for filter integrity, particulate contamination, microbiological
cleanliness of chambers, sterility of prepared doses, sterility of partially
used vials, precision of preparation, correct vial recognition, accuracy of
final-container labeling and software reliability. CytoCare(TM) is still the
best in the world, there's nothing to beat it. CytoCare(TM) creates a
beautiful aseptic environment, free of microorganisms and particles. Other
robots push-and-pull or suck-and-blow, CytoCare(TM) represents a far greater
level of complexity. We have also esti
|SOURCE Health Robotics SRL|
Copyright©2009 PR Newswire.
All rights reserved